Side-by-side comparison of AI visibility scores, market position, and capabilities
Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. difficile.
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic diseases. The company is focused on two primary therapeutic areas: gastrointestinal infections including C. difficile and conditions involving the gut-brain axis including autism spectrum disorder where gut microbiome alterations have been associated with symptom severity. Finch's lead microbiome program CP101 targets recurrent C. difficile infection, competing in the same emerging microbiome therapeutics space as Seres Therapeutics. The company also conducts research on the COMET platform for autism spectrum disorder, exploring whether microbiome restoration can improve behavioral symptoms through the gut-brain connection. Finch has raised over $165M and has conducted multiple clinical trials of its microbiome medicines. The company's autism program represents a particularly innovative and scientifically ambitious program given the emerging evidence that gut microbiome composition influences neurological development and behavior. Finch's work contributes to the broader scientific validation of microbiome medicine as a legitimate therapeutic class beyond C. difficile.
Indoor vertical farming company using AI-optimized growing systems. San Francisco, CA. Raised $940M+ including $400M from SoftBank. Partners with Walmart for US farms.
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has raised over $940 million from investors including SoftBank Vision Fund, which invested $200 million in 2017, and has positioned itself as the technology leader in data-driven indoor agriculture.\n\nPlenty's farms use precisely controlled light, temperature, humidity, and nutrient conditions to grow crops that are free from pesticides, use 99% less land, and consume significantly less water than conventional field agriculture. The company's AI systems continuously optimize growing conditions based on sensor data, learning to improve yields and quality across crops and growing cycles.\n\nIn 2022, Plenty announced a landmark partnership with Walmart to supply leafy greens from a new large-scale facility in Compton, California. This partnership provided both a major commercial anchor and significant additional funding from Walmart, validating Plenty's technology and business model at scale. The company also operates a dedicated strawberry R&D partnership with Driscoll's, the world's largest berry company, demonstrating the platform's potential beyond leafy greens.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.